Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nkarta

1.63
-0.0750-4.40%
Post-market: 1.60-0.0300-1.84%19:02 EDT
Volume:1.16M
Turnover:1.88M
Market Cap:115.66M
PE:-1.02
High:1.70
Open:1.63
Low:1.59
Close:1.71
Loading ...

Company Profile

Company Name:
Nkarta
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
157
Office Location:
1150 Veterans Boulevard,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Directors

Name
Position
Ali Behbahani
Chairman and Director
Paul Hastings
President, Chief Executive Officer and Director
Fouad Azzam
Director
Laura Shawver
Director
Leone Patterson
Director
Michael Dybbs
Director
Simeon George
Director
Tiba Aynechi
Director
Zachary Scheiner
Director

Shareholders

Name
Position
Paul Hastings
President, Chief Executive Officer and Director
Matthew Plunkett
Chief Financial Officer
James Trager
Chief Scientific Officer
Kanya Rajangam
Chief Medical Officer
Nadir Mahmood
Chief Business Officer